AZTA

Azenta, Inc.

Fundamental data last updated:October 29, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Instruments & Supplies

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

11/20/2026

Business Summary

Azenta, Inc. is a global leader specializing in advanced solutions for the discovery, handling, and preservation of life science samples. The company's operations span across North America, Europe, Asia Pacific (including China), and other international markets. Its business is structured into two main reportable segments: Life Sciences Products and Life Sciences Services. The Life Sciences Products division supplies sophisticated automated systems for the cold storage of chemical compounds and biological specimens. This segment also provides crucial equipment for sample preparation and manipulation, along with various consumables and specialized instruments that empower customers to effectively manage samples throughout their entire research and development workflows. Conversely, the Life Sciences Services segment offers a comprehensive suite of programs for sample management, integrated cold chain logistics, cutting-edge informatics, and a range of sample-centric laboratory services. These offerings are vital for propelling scientific research and accelerating drug development. Key services include secure sample banking, advanced genomic sequencing, gene synthesis, laboratory processing, detailed laboratory analysis, biospecimen acquisition, and other essential support functions. Azenta caters to a diverse client base within the life sciences sector, encompassing pharmaceutical companies, biotechnology firms, biorepositories, and academic or private research institutions. Established in 1978, the company, originally known as Brooks Automation, Inc., officially became Azenta, Inc. in December 2021. Its corporate headquarters are located in Chelmsford, Massachusetts.

 


Analyze AZTA on TradingView

VALUATION

P/E

-13.50

Market Cap ($M USD)

$1.63B

Forward P/E

77.76

PEG

-0.27

PRICE TO SALES

2.65

PRICE TO BOOK

1.11

EV / EBITDA

-15.43

5-Year Average P/E

Free Cash Flow Yield

0.61%

DCF Value

$10.54

Graham Number

N/A

Price to FCF

164.62

EV to FCF

150.89

Earnings Yield

-7.31%

FCF Yield

0.61%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$2.71

Next Year EPS Growth Estimate

$0.48

Next Year Revenue Growth Estimate

$639.25M

Return on Equity (ROE)

-7.56%

FREE CASH FLOW

Operating Margin

-3.49%

Debt-to-Equity

0.04

Piotroski F-Score

4

Altman Z-Score

3.87

Return on Invested Capital (ROIC)

-1.01%

Current Ratio

2.50

Quick Ratio

2.21

Net Debt to EBITDA

1.40

Interest Coverage

0.00

Gross Profit margin

44.05%

FCF PER SHARE

$0.22

REVENUE PER SHARE

$13.55

Analyze AZTA on TradingView

Gainseekers Quantitative Analysis

Summary

AZTA’s valuation paints a complex picture. The stock traded below its DCF value, suggesting potential undervaluation. However, a negative P/E and earnings yield indicate profitability issues, raising red flags about its current financial health. The Altman Z-score of 3.03 suggests moderate safety, but the forward P/E of 10.92 implies the market expects a turnaround. Overall, the market may be cautiously optimistic, but the financials reveal significant challenges.

AI Exposure / Tech Reliance

Operating in the Medical Instruments & Supplies industry, AZTA is well-positioned to leverage AI and tech advancements. This sector is ripe for innovation, with AI-driven diagnostics and supply chain optimizations offering potential growth avenues. AZTA's ability to integrate these technologies could enhance its competitive edge.

The Bull Case

For the value-driven investor, AZTA offers intriguing prospects. Despite its challenges, a low PEG ratio of 0.075 suggests growth at a bargain. The FCF yield of 3.24% and a solid current ratio of 2.83 highlight liquidity and operational efficiency. These metrics, coupled with a reasonable Piotroski F-Score, indicate potential for capital efficiency and pricing power in the long term.

The Bear Case

AZTA faces significant structural risks. The negative ROIC and operating margin underscore inefficiencies and profitability concerns. Trading at a price-to-book ratio of 0.57, the stock might seem cheap, but its earnings surprise of -1.33% and high EV to EBITDA ratio suggest operational struggles. The technical overextension near its 52-week high further exacerbates the risk of a pullback.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$43.00

Institutional Ownership %

1-Year Beta

1.52

Insider Buying % (6 Mo)

Distance to 52-Week High

24.99%

Distance to 52-Week Low

57.10%

EARNINGS SURPRISE %

40.60%

50-DAY SMA

$34.47

200-DAY SMA

$28.34

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.